• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
COVID-19 Management

CDC Reports on the Risk of Myocarditis with COVID-19 Vaccination

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • There have been reports of myocarditis and pericarditis in mRNA COVID-19 vaccine recipients, primarily among young males receiving their second dose
  • Gargano et al. (CDC MMWR, 2021) report on the incidence of myocarditis following mRNA vaccination, and assessed the benefit-risk balance of mRNA vaccines in adolescents and young adults

METHODS:

  • Population
    • Within the Vaccine Adverse Event Reporting System (VAERS)
      • Individuals administered an mRNA-based COVID-19 vaccine in the U.S.
    • In CDC rapid review of myocarditis
      • A subset of individuals aged <30 years who met CDC’s case definitions for myocarditis
  • Study design
    • To assess the benefit-risk balance of mRNA vaccines in adolescents and young adults, an individual-level assessment compared benefits (i.e., COVID-19 infections and severe disease prevented) to risks (number of cases of myocarditis)
      • Analysis assumed 95% vaccine effectiveness and assessed outcomes for a 120-day period

RESULTS:

  • 296 million doses of mRNA COVID-19 vaccines administered as of June, 2021
    • 52 million doses administered to persons aged 12 to 29 years
  • Reports of myocarditis after vaccination between December 29, 2020 and June 11, 2021 in VAERS: 1,226 reports
    • Median age: 26 years (range 12 to 94 years)
    • Median symptom onset: 3 days after vaccination (range 0 to 179 days)
    • Among 1212 cases of myocarditis with sex reported
      • Male: 923 cases
      • Female: 289 cases
    • Among 1094 cases of myocarditis with number of vaccine doses reported
      • After dose 1: 24%
      • After dose 2: 76%
  • Myocarditis in CDC review: 323 cases
    • Median age: 19 years (range 12 to 29 years)
    • The median symptom onset: 2 days (range 0 to 40 days)
      • 92% experienced onset with 7 days of vaccination
    • Sex reporting ratio
      • Male: 291 cases
      • Female: 32 cases
    • Hospitalizations: 96%
      • Acute clinical courses were generally mild
      • Discharges among hospitalized patients: 95%
      • No deaths
  • Myocarditis reporting rates in VAERS
    • Males
      • Aged 12 to 29 years: 40.6 cases per million second doses
      • Aged ≥30 years: 2.4 per million second doses
    • Females
      • Aged 12 to 29 years: 4.2 cases per million second doses
      • Aged ≥30 years: 1.0 per million second doses
  • The benefits of vaccination outweighed the risks in all populations for which vaccination has been recommended
    • Per million second doses of mRNA COVID-19 vaccine administered to males aged 12 to 29 years
      • Benefits: 11,000 COVID-19 cases, 560 hospitalizations, 138 ICU admissions, and six deaths due to COVID-19 prevented
      • Risks: 39 to 47 expected myocarditis cases
    • Among males aged ≥30 years
      • Benefits: 15,300 COVID-19 cases, 4,598 hospitalizations, 1,242 ICU admissions, and 700 deaths prevented
      • Risks: 3 to 4 expected myocarditis cases

CONCLUSION:

  • Myocarditis is a rare complication of mRNA-based COVID-19 vaccination, with 1,226 reports in the US, out of 296 million doses administered
  • Myocarditis is more common in males under the age of 30 receiving their second dose,
    • Cases in this population remain rare, with a reporting rate of 40.6 cases per million second doses
  • The clinical course of myocarditis cases is generally mild
    • No deaths have been reported
  • The Advisory Committee on Immunization Practices (ACIP) has concluded that the benefits of vaccination outweigh risks regarding myocarditis in all populations in which vaccination has been recommended

Learn More – Primary Sources:

Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021

Get Mobile-Friendly COVID-19 Research Summaries with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 Management Posts
Next >

Related ObG Topics:

COVID-19 mRNA Vaccine Effectiveness in the Real World Including in Those Partially Immunized
An Update on COVID-19 Vaccine Related Anaphylaxis: Cases Remain Rare
How Common are Anaphylaxis and Allergic Reactions Following Pfizer-BioNTech COVID-19 Vaccination?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site